Establishment Labs Holdings Inc. revenue
Establishment Labs Holdings Inc.'s revenue was $211m in fiscal 2025, up 27.1% on the year before. Since fiscal 2017 ($34.7m) it has grown at a compound 25.3% a year. Over the last twelve months it was $246m.
Revenue history
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35 | 61 | 90 | 85 | 127 | 162 | 165 | 166 | 211 | 246 |
| Growth on the year before | — | +76.5% | +46.3% | −5.5% | +49.6% | +27.6% | +2.1% | +0.5% | +27.1% | — |
| Gross profit | 18 | 36 | 55 | 53 | 85 | 107 | 107 | 110 | 146 | 173 |
| Gross margin | 51.0% | 59.0% | 61.3% | 62.0% | 67.4% | 65.9% | 64.8% | 66.0% | 69.3% | 70.5% |
Where the revenue comes from
| Region | Revenue | Share | YoY |
|---|---|---|---|
| EMEA | $91.1M | 43.1% | ▲ 16.4% |
| North America | $45.6M | 21.6% | ▲ 933.0% |
| Latin America | $39.9M | 18.9% | ▲ 14.1% |
| Asia Pacific | $34.5M | 16.4% | ▼ 28.6% |
From Establishment Labs Holdings Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Establishment Labs Holdings Inc. | $246m | 38.6% | 11.5% |
| Cerus Corp | $254m | 74.6% | 89.8% |
| Lemaitre Vascular Inc | $262m | 11.8% | 14.0% |
| Orthopediatrics Corp | $264m | 16.1% | 23.0% |
| Axogen, Inc. | $267m | 24.3% | 20.6% |
| Si-bone, Inc. | $214m | 15.3% | 19.7% |
Compare with peers
- Cerus Corp revenue
- Lemaitre Vascular Inc revenue
- Orthopediatrics Corp revenue
- Axogen, Inc. revenue
- Si-bone, Inc. revenue
Head to head: CERS vs ESTAESTA vs LMATESTA vs KIDSESTA vs SIBN
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies